Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	305,137	956,826	1,272,626	2,077,519
Depreciation	271	436	966	1,308
Research and development (including stock-based compensation (Note 7))	103,529	680,436	387,442	1,125,937
Total operating expenses	408,937	1,637,698	1,661,034	3,204,764
Loss from operations	(408,937)	(1,637,698)	(1,661,034)	(3,204,764)
Other expense (income):
Gain on extinguishment of liabilities				(718,580)
Conversion inducement		8,000		8,000
Interest expense	100,282	84,714	290,082	276,815
Total other expense (income)	100,282	92,714	290,082	(433,765)
Net loss	(509,219)	(1,730,412)	(1,951,116)	(2,770,999)
Net loss attributable to the noncontrolling interest	505	1,472	4,197	2,486
Net loss applicable to Bion's common stockholders	$ (508,714)	$ (1,728,940)	$ (1,946,919)	$ (2,768,513)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.01)	$ (0.07)	$ (0.07)	$ (0.11)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	26,842,776	24,465,814	26,291,097	24,253,807